Safety and tolerability in cSSTIs
Both therapy groups exhibited comparable incidences of treatment-emergent AEs. Pruritus was more frequent in the vancomycin plus aztreonam group versus the ceftaroline group (8.2% vs. 3.5%). A possible allergic reaction was the most prominent factor for premature discontinuation of the therapy intervention (1.9% for ceftaroline, 2.9% for vancomycin and 2.9% for aztreonam).3
Header | ||
---|---|---|
Header | Header | Header |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Adapted from Corey GR, et al. 2010.
Please refer to the full Prescribing Information for the complete list of AEs.
*Comparators from the ZINFORO® clinical trials for the treatment of CAP and cSSTI.2
AE, adverse event; CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue infection.
References:
Example
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.